Drug Discovery World
AUGUST 8, 2023
Ginkgo Bioworks and Merck have collaborated to improve the production of biologics. “In particular, we will utilise some of our unique capabilities, such as automated protocols to do predictive ultra high-throughput multiplexed screening, product characterisation and process optimisation. .”
The Pharma Data
JUNE 7, 2023
Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch. at the BioProcess International Theater.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
APRIL 11, 2024
Moreover, rather than producing antibodies, the cancer cells produce abnormal proteins that can cause complications. J&J and Legend have been working to increase their manufacturing capacity as the second-line approval is expected to significantly expand the number of patients who will be eligible for Carvykti. “We
Pharmaceutical Technology
APRIL 28, 2023
The company undertook several initiatives recently to expand its business through new partnerships, expansion of existing relationships, and investment in manufacturing capacity. Initially centered on Librela®, this agreement paves the way for developing and manufacturing other molecules in the coming years. until 2026.
Drug Discovery World
MARCH 13, 2023
While there is no silver bullet for increasing the availability of CGTs, improving manufacturing processes that enable their development at scale can help reduce the cost of these treatments and get them to those who need them most. Planning—without hoarding resources—is everything.
The Pharma Data
OCTOBER 27, 2020
MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and treatment of COVID-19, with the possibility to manufacture at scale, easy administration and with the potential to bypass cold storage. During the clinical development stage, Molecular Partners will provide clinical supply.
The Pharma Data
NOVEMBER 22, 2020
MP0420 is designed to bind the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein at three distinct locations to prevent viral entry into cells. MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program.
Expert insights. Personalized for you.
52 
Let's personalize your content